Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma.

Abstract

AIM:

To investigate the inhibitory effect of in vivo expression of expressing plasmid pCH510 of recombinant fibronectin polypeptide (CH50) on hepatocellular carcinoma and the improved therapeutic effect of pCH510 in combination with chemotherapeutic agents and Hsp70-H22 hepatocarcinoma antigen peptide on tumor.

METHODS:

Mice were inoculated with H22 hepatocarcinoma cells. The chemotactic effect of the expression of plasmid pCH510 on immunocytes was observed after in vivo transfection, tissue slicing and HE staining. Inhibitory effect of transfection with pCH510 on murine tumor originated from different inoculative doses was observed. The inhibitory effect of immediate transfection with pCH510 after chemotherapy on tumor was compared with that of transfection 5 days after chemotherapy. The change of function and amount of mouse peritoneal macrophages and the peripheral blood immunocytes resulted from administration of chemotherapeutic agents were detected. The peptides mixture was prepared from H22 hepatocarcinoma cells. pCH510 + Hsp70-H22 antigen peptides were injected into tumor-bearing mice with or without chemotherapy, to observe the inhibitory effects on tumor.

RESULTS:

At the tumor tissue site injected with pCH510, there were a great number of immunocytes which mainly were macrophages, lymphocytes and neutrophils. Transfection of plasmid pCH510 inhibited significantly the murine tumor induced by different inoculative doses. The inhibitory effect was negatively correlated with the inoculative dose. The therapeutic effect was not improved by immediate transfection with pCH510 after chemotherapy, but was significantly improved by transfection with pCH510 5 days after chemotherapy. Chemotherapeutic agent decreased the number of immunocytes and suppressed their activation in vivo. After injection of drug, the amount of immunocytes was the lowest from d 1 to d 3 and returned to normal level on the 10(th) day. Transfection with plasmid pCH510 alone could inhibit tumor induced by the inoculation with 10(4) H22 cells. The tumor originated from the inoculation with 10(5) H22 cells was inhibited by pCH510+Hsp70-H22 antigen peptides and that from the inoculation with 10(6) H22 cells was inhibited by pCH510+Hsp70-H22 antigen peptides in combination with chemotherapeutic agents.

CONCLUSION:

In vivo expression of pCH510 recruits immune cells, inhibits tumor growth, and enhances the efficacy of chemotherapy. But the proper timing of combining chemotherapy with pCH510 must be taken into great account. The synergism of pCH510 and Hsp70-H22 peptides can improve the efficacy, which could be further enhanced if they are used following chemotherapy. Chemotherapeutic agent + pCH510 + Hsp70-H22 peptides is a promising therapeutic approach of combination treatment of tumor.

• Authors: Gui-Mei Zhang, Yan Yang, Bo Huang, Hui Xiao, Dong Li, Zuo-Hua Feng
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 9 Issue 9 Pg. 1940-5 (Sep 2003) ISSN: 1007-9327 [Print] United States
• PMID: 12970880 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• CH50 recombinant polypeptide
• Fibronectins
• Peptide Fragments
• Recombinant Proteins

Topics

• Animals
• Carcinoma, Hepatocellular (pathology)
• Cell Division (drug effects)
• Fibronectins (pharmacology)
• Humans
• Liver Neoplasms (pathology)
• Mice
• Peptide Fragments (pharmacology)
• Recombinant Proteins (pharmacology)
• Tumor Cells, Cultured